Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000469599 | SCV000551954 | likely pathogenic | Hereditary nonpolyposis colon cancer | 2019-12-19 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 5 of the PMS2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs758304323, ExAC 0.009%). This variant has been observed in individuals affected with Lynch syndrome (PMID: 28449805, 28640387). ClinVar contains an entry for this variant (Variation ID: 411028). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Counsyl | RCV000663281 | SCV000786518 | pathogenic | Hereditary nonpolyposis colorectal cancer type 4 | 2018-05-17 | criteria provided, single submitter | clinical testing | |
| Color | RCV000775368 | SCV000909676 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2018-09-21 | criteria provided, single submitter | clinical testing | |
| Laboratory for Molecular Medicine, |
RCV000825602 | SCV000966945 | likely pathogenic | Lynch syndrome | 2017-12-27 | criteria provided, single submitter | clinical testing | The c.538-2A>G variant in PMS2 has been reported in at least 1 Hispanic individu al with PMS2-associated cancer and absence of PMS2 staining via IHC in their tum or sample (Sunga 2017, Ricker 2017). It has also been identified in 3/33582 of L atino chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broa dinstitute.org/; dbSNP rs758304323). This frequency is low enough to be consiste nt with the frequency of Lynch syndrome in the general population. This variant occurs in the invariant region (+/- 1,2) of the splice consensus sequence and is predicted to cause altered splicing leading to an abnormal or absent protein. A nother variant (c.538-3C>G) impacting the same splice region was shown to result in two aberrant RNA transcripts (in-frame skipping of exon 6 and a 49-bp deleti on producing a frameshift) in an affected carrier (Borras 2013). Furthermore, a large deletion resulting in the in-frame loss of exon 6 was classified as pathog enic on September 5, 2013 by the ClinGen-approved InSiGHT expert panel (ClinVar SCV000108368.2). In summary, although additional studies are required to fully e stablish its clinical significance, the c.538-2A>G variant is likely pathogenic. ACMG/AMP Criteria applied: PM4, PM5, PP3, PP4. |
| Ambry Genetics | RCV000775368 | SCV001185960 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-01-30 | criteria provided, single submitter | clinical testing | Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (b-level) evidence supporting pathogenicity;Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation;In silico models in agreement (deleterious) and/or completely conserved position in appropriate species;Other data supporting pathogenic classification |
| Integrated Genetics/Laboratory Corporation of America | RCV000825602 | SCV001338459 | likely pathogenic | Lynch syndrome | 2020-04-10 | criteria provided, single submitter | clinical testing | Variant summary: PMS2 c.538-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3 acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 1.2e-05 in 251470 control chromosomes (gnomAD). c.538-2A>G has been reported in the literature in individuals affected with Lynch syndrome and colorectal cancer (Sunga_2017, Ricker_2017, Mork_2019). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters (evaluation after 2014) cite the variant as pathogenic (2x) and likely pathogenic (3x). Based on the evidence outlined above, the variant was classified as likely pathogenic. |